| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| - | - | 4,700 | ₹4 0% | 1,6250% |
| - | - | 4,800 | ₹2.45 0% | 1,2500% |
| - | - | 4,900 | ₹2.75 37.5% | 4,00018.51% |
| - | - | 4,950 | ₹2 -48.71% | 16,500-1.49% |
| 5000% | ₹568 0% | 5,000 | ₹3.55 -29% | 1,37537.5% |
| 3750% | ₹623.15 0% | 5,050 | ₹12.9 0% | 1,1250% |
| 5,1250% | ₹497.15 0% | 5,100 | ₹4.5 -40.78% | 20,750-5.14% |
| - | - | 5,150 | ₹5.5 -68.48% | 2,125-10.52% |
| - | - | 5,200 | ₹5.4 -37.93% | 8,0004.91% |
| - | - | 5,250 | ₹7.5 -64.62% | 1250% |
| - | - | 5,300 | ₹9.25 -46.53% | 4,000146.15% |
| - | - | 5,350 | ₹54.45 0% | 1,0000% |
| 2,000-11.11% | ₹433.45 70.18% | 5,400 | ₹13.95 -48.04% | 15,2506.08% |
| 1,625-31.57% | ₹343.85 46.53% | 5,450 | ₹18.5 -46.91% | 10,87517.56% |
| 12,125-6.73% | ₹342.75 53.32% | 5,500 | ₹24.05 -47.94% | 13,625-22.14% |
| 7,250-13.43% | ₹290.5 56.51% | 5,550 | ₹32.35 -46.7% | 7,62517.30% |
| 20,500-20.38% | ₹252 65.84% | 5,600 | ₹41.5 -46.76% | 12,62527.84% |
| 6,000-12.72% | ₹220 79% | 5,650 | ₹54.3 -61.28% | 5,125310% |
| 11,000-39.72% | ₹188.95 88.95% | 5,700 | ₹69.1 -44.02% | 10,125189.28% |
| 2,3750% | ₹152.4 0% | 5,750 | - | - |
| 35,87543.5% | ₹129.6 102.97% | 5,800 | ₹110.75 -60.62% | 7,1252750% |
| 3,5000% | ₹102.15 0% | 5,850 | - | - |
| 17,250220.93% | ₹86.95 126.43% | 5,900 | - | - |
| 3,8750% | ₹21.05 0% | 5,950 | - | - |
| 29,62522.79% | ₹55.6 145.47% | 6,000 | - | - |
| 2,0000% | ₹43.25 0% | 6,050 | - | - |
| 8,25043.47% | ₹35 157.35% | 6,100 | - | - |
| 3,3750% | ₹9.05 0% | 6,150 | - | - |
| 12,8752475% | ₹22.5 383.87% | 6,200 | - | - |
| 5,750475% | ₹14.5 8.61% | 6,300 | - | - |
| 9,125329.41% | ₹9.95 158.44% | 6,400 | ₹679.15 0% | 7500% |
| 3,5001300% | ₹6.8 44.68% | 6,500 | - | - |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
